Loading...

PE anti-mouse CD279 (PD-1) Antibody

Pricing & Availability
Clone
29F.1A12 (See other available formats)
Regulatory Status
RUO
Other Names
PD-1, Programmed Death-1, PDCD1
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
A_29F.1A12_PE_100909
Con-A and IL-2 stimulated (3 days) C57BL/6 splenocytes stained with 29F.1A12 PE and CD3 (145-2C11) APC
  • A_29F.1A12_PE_100909
    Con-A and IL-2 stimulated (3 days) C57BL/6 splenocytes stained with 29F.1A12 PE and CD3 (145-2C11) APC
  • B_29F.1A12_PE_100909
    Con A stimulated (3 days) C57BL/6 splenocytes stained with rat IgG2a isotype PE and CD3e (145-2C11) APC
See PE spectral data
Cat # Size Price Quantity Check Availability Save
135205 50 µg 96€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
135206 200 µg 248€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells and thymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyte clonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positive selection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation is essential for prolonged survival of intratesticular islet allografts.

Product Details
Technical data sheet

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
PD-1 cDNA followed by PD-1-Ig fusion protein
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6.

Application References

(PubMed link indicates BioLegend citation)
  1. Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed
  2. Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block)
  3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block)
  4. Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed
  5. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  6. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Fortner K, et al. 2017. Journal of Autoimmunity. 10.1016/j.jaut.2017.05.003. PubMed
  2. Schell S, et al. 2017. J Immunol. 10.4049/jimmunol.1700611. PubMed
  3. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  4. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  5. Beloor J et al. 2018. Cell host & microbe. 23(4):549-556 . PubMed
  6. Wang GZ, et al. 2019. Nat Commun. 10:1125. PubMed
  7. Liu J, et al. 2019. J Exp Med. 216:656. PubMed
  8. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  9. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  10. Mintz MA, et al. 2019. Immunity. 51:310. PubMed
  11. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  12. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  13. Russell SL, et al. 2019. Cell Rep. 29:3564. PubMed
  14. Fusciello M, et al. 2019. Nat Commun. 4.407638889. PubMed
  15. Pham D, et al. 2019. Cell Rep. 29:1203. PubMed
  16. Moufarrij S, et al. 2020. Sci Rep. 10:3470. PubMed
  17. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  18. Spitsin S, et al. 2012. Clin Vaccine Immunol. 1.313888889. PubMed
  19. Soni C, et al. 2014. J Immunol. 193:4400. PubMed
  20. Wong E, et al. 2015. J Immunol. 194:4130. PubMed
  21. Domeier P, et al. 2016. J Exp Med. 213: 715 - 732. PubMed
  22. Zhang YN, et al. 2020. EBioMedicine. 56:102819. PubMed
  23. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  24. Huang WC, et al. 2020. Adv Mater. 32:e2005637. PubMed
  25. Zhang X, et al. 2020. Endocr Relat Cancer. 27:469. PubMed
  26. Soni C, et al. 2020. Immunity. 52(6):1022-1038.e7. PubMed
  27. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  28. Kaczanowska S, et al. 2021. Cell. 184(8):2033-2052.e21. PubMed
  29. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  30. Lu SX, et al. 2021. Cell. . PubMed
  31. Gary EN, et al. 2021. iScience. 24(7):102699. PubMed
  32. Hamdan F, et al. 2021. Journal for ImmunoTherapy of Cancer. 9(8):. PubMed
  33. Roberto MP, et al. 2021. Immunity. 54(8):1807-1824.e14. PubMed
  34. Renrick AN, et al. 2021. Front Immunol. 607044:12. PubMed
  35. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  36. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  37. Hamilton JAG, et al. 2021. Aging Cell. 20:e13309. PubMed
  38. Ekeke CN, et al. 2020. J Thorac Cardiovasc Surg. S0022-5223:33337. PubMed
  39. Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed
  40. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  41. Feizi N, et al. 2021. Cell Death Dis. 12:1026. PubMed
  42. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
  43. Kummer MP, et al. 2021. EMBO J. 40:e108662. PubMed
  44. Cai B, et al. 2021. Mol Cancer. 20:165. PubMed
  45. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  46. Lin YN, et al. 2022. Oncoimmunology. 11:2027136. PubMed
  47. Stolp B, et al. 2022. Cell Rep. 38:110387. PubMed
  48. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  49. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  50. Kramer KJ, et al. 2022. Nat Commun. 13:3466. PubMed
  51. Zhang X, et al. 2021. Front Immunol. 12:680068. PubMed
  52. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  53. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  54. Zhang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  55. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  56. Sasse C, et al. 2022. Pathogens. 11:. PubMed
  57. Wei W, et al. 2022. mSystems. 7:e0046922. PubMed
  58. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  59. Zhang Z, et al. 2022. J Inflamm Res. 15:5595. PubMed
  60. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  61. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  62. Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed
  63. Serra M, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:609. PubMed
  64. Liu M, et al. 2022. Cells. 11: . PubMed
  65. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  66. Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed
  67. Domingos-Pereira S, et al. 2022. Int J Mol Sci. 24: . PubMed
  68. Wei J, et al. 2022. Cancer Prev Res (Phila). 15:285. PubMed
  69. Wight AE, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200757119. PubMed
  70. Wu Z, et al. 2023. EMBO Rep. 24:e56524. PubMed
  71. Hamdan F, et al. 2023. Mol Ther Oncolytics. 28:264. PubMed
  72. Florian DC, et al. 2023. Cancer Res Commun. 3:223. PubMed
  73. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  74. Nishi W, et al. 2023. Nat Commun. 14:3157. PubMed
  75. Yang QC, et al. 2023. iScience. 26:106916. PubMed
RRID
AB_1877232 (BioLegend Cat. No. 135205)
AB_1877231 (BioLegend Cat. No. 135206)

Antigen Details

Structure
A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.
Distribution

Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.

Function
Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.
Ligand/Receptor
B7-H1 (PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, T cells
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Nishimura H, et al. 2001. Science 291:319
2. Agata Y, et al. 1996. Int. Immunol. 8:765
3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706
4. Barber DL, et al. 2006. Nature 439:682
5. Keir ME, et al. 2005. J. Immunol. 175:7372
6. Koehn BH. et al. 2008. J Immunol. 181:5313

Gene ID
18566 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 3    Revision Date: 09.11.2014

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account